JP2000510435A - アデノウイルスe1aを用いて腫瘍細胞を感作する方法 - Google Patents
アデノウイルスe1aを用いて腫瘍細胞を感作する方法Info
- Publication number
- JP2000510435A JP2000510435A JP08509670A JP50967096A JP2000510435A JP 2000510435 A JP2000510435 A JP 2000510435A JP 08509670 A JP08509670 A JP 08509670A JP 50967096 A JP50967096 A JP 50967096A JP 2000510435 A JP2000510435 A JP 2000510435A
- Authority
- JP
- Japan
- Prior art keywords
- tumor cells
- polypeptide
- nucleic acid
- subject
- introducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒト腫瘍細胞を処置する方法であって、以下の工程: a.該腫瘍細胞に、E1A活性を有するポリペプチドをコードする核酸を導入 する工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該腫瘍細胞を化学療法剤と接触させる工程、 を包含する方法。 2.前記核酸がアデノウイルスE1Aポリペプチドをコードする、請求項1に記 載の方法。 3.前記導入する工程がインビトロで行われる、請求項1に記載の方法。 4.前記導入する工程がインビボで行われる、請求項1に記載の方法。 5.前記核酸が、前記腫瘍細胞中に、該細胞を前記核酸配列を含む適切なレト ロウイルスベクターと接触させることにより導入される、請求項1に記載の方法 。 6.前記化学療法剤が、エトポシド、アドリアマイシン、アムサクリン、アク チノマイシンD、VP16、カンプトテシン、コルヒチン、タキソール、シスプ ラチン、ビンクリスチン、ビンブラスチン、およびメトトレキセートからなる群 から選択される、請求項1に記載の方法。 7.ヒト腫瘍細胞を処置する方法であって、以下の工程: a.該腫瘍細胞に、E1A活性を有するポリペチドをコードする核酸を導入す る工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該腫瘍細胞に放射線照射する工程、 を包含する方法。 8.前記核酸がアデノウイルスE1Aポリペプチドをコードする、請求項7に記 載の方法。 9.前記導入する工程がインビトロで行われる、請求項7に記載の方法。 10.前記導入する工程がインビボで行われる、請求項7に記載の方法。 11.前記核酸が、前記腫瘍細胞中に、該細胞を前記核酸配列を含む適切なレ トロウイルスベクターと接触させることにより導入される、請求項7に記載の方 法。 12.被験体における化学療法に対する応答を増強する方法であって、以下の 工程: a.該被験体の腫瘍細胞に、E1A活性を有するポリペチドをコードする核酸 を導入する工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該被験体に化学療法剤を投与する工程、 を包含する方法。 13.前記導入する工程(a)が前記被験体への直接注入による、請求項12 に記載の方法。 14.前記導入する工程(a)が、被験体から単離された腫瘍細胞の集団に対 して行われ、次いで該細胞が該被験体に戻される、請求項12に記載の方法。 15.前記核酸がアデノウイルスE1Aポリペプチドをコードする、請求項12 に記載の方法。 16.被験体において放射線照射に対する応答を増強する方法であって、以下 の工程: a.該被験体の腫瘍細胞に、E1A活性を有するポリペチドをコードする核酸 を導入する工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該被験体に放射線照射を施す工程、 を包含する方法。 17.前記導入する工程(a)が前記被験体への直接注入による、請求項16 に記載の方法。 18.前記導入する工程(a)が、被験体から単離された腫瘍細胞の集団に対 して行われ、次いで該細胞が該被験体に戻される、請求項16に記載の方法。 19.前記核酸がアデノウイルスE1Aポリペプチドをコードする、請求項16 に記載の方法。 20.処置に感受性である癌を処置する方法であって、以下の工程: a.被験体の腫瘍細胞に、アデノウイルスE1A活性を有するポリペチドをコ ードする核酸を導入する工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該腫瘍細胞を化学療法剤と接触させる工程、 を包含する方法。 21.処置に感受性である癌を処置する方法であって、以下の工程: a.被験体の腫瘍細胞に、アデノウイルスE1A活性を有するポリペチドをコ ードする核酸を導入する工程; b.該腫瘍細胞において該ポリペプチドを発現させる工程;および c.該腫瘍細胞に放射線照射する工程、 を包含する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/301,316 US5776743A (en) | 1994-09-06 | 1994-09-06 | Method of sensitizing tumor cells with adenovirus E1A |
US08/301,316 | 1994-09-06 | ||
PCT/US1995/011342 WO1996007322A1 (en) | 1994-09-06 | 1995-09-05 | Method of sensitizing tumor cells with adenovirus e1a |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000510435A true JP2000510435A (ja) | 2000-08-15 |
Family
ID=23162849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP08509670A Ceased JP2000510435A (ja) | 1994-09-06 | 1995-09-05 | アデノウイルスe1aを用いて腫瘍細胞を感作する方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5776743A (ja) |
EP (1) | EP0781092B1 (ja) |
JP (1) | JP2000510435A (ja) |
AT (1) | ATE266425T1 (ja) |
CA (1) | CA2199265A1 (ja) |
DE (1) | DE69533036T2 (ja) |
DK (1) | DK0781092T3 (ja) |
ES (1) | ES2216018T3 (ja) |
PT (1) | PT781092E (ja) |
WO (1) | WO1996007322A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
US6326356B1 (en) | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
CA2234060A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
WO1997035012A1 (en) * | 1996-03-20 | 1997-09-25 | Board Of Regents, The University Of Texas System | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
US6248351B1 (en) | 1997-01-10 | 2001-06-19 | Board Of Regents,The University Of Texas System | Human PEA3 is a tumor suppressor for cancer cells |
US5922688A (en) | 1997-01-10 | 1999-07-13 | Board Of Regents, The University Of Texas System | PEA3 is a tumor suppressor |
US20040048821A1 (en) * | 1997-06-27 | 2004-03-11 | Cold Spring Harbor Laboratory | Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene |
AU771224B2 (en) | 1998-07-13 | 2004-03-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6552005B1 (en) * | 1998-09-29 | 2003-04-22 | Uab Research Foundation | Molecular chemotherapy enhancement of radiotherapy |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
US7048920B2 (en) * | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
NZ525552A (en) | 2000-11-09 | 2005-04-29 | Neopharm Inc | SN-38 lipid complexes with cardiolipin and methods of use for the treatment of cancers and multiple sclerosis |
AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
AU2002252160A1 (en) * | 2001-03-01 | 2002-09-19 | Northwest Biotherapeutics, Inc. | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
FR2821748A1 (fr) * | 2001-03-12 | 2002-09-13 | Laurent Schwartz | Utilisation d'un principe actif anti-fibrose pour la preparation d'un medicamment destine a la prevention du cancer broncho-pulmonaire |
US20020169126A1 (en) * | 2001-03-21 | 2002-11-14 | Mien-Chie Hung | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene |
US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
ATE554781T1 (de) * | 2002-05-10 | 2012-05-15 | Oncolytics Biotech Inc | Onkolytische viren zur sensibilisierung neoplastischer zellen für die strahlentherapie |
EP2269656B1 (en) | 2002-07-15 | 2014-08-20 | Board Of Regents, The University Of Texas | Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20040191761A1 (en) * | 2003-03-27 | 2004-09-30 | Routes John M. | Modified adenoviral E1A constructs and methods of use thereof |
FR2858460B1 (fr) * | 2003-07-30 | 2005-10-14 | Soitec Silicon On Insulator | Structure semiconducteur-sur-isolant contrainte ayant une tenue des contraintes aux hautes temperatures |
US7879545B2 (en) * | 2003-11-05 | 2011-02-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier |
KR20170102377A (ko) | 2004-01-22 | 2017-09-08 | 유니버시티 오브 마이애미 | 국소용 코-엔자임 큐10 제형 및 그의 사용 방법 |
WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
CA2640286C (en) * | 2006-02-13 | 2018-01-02 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
EP2136831B1 (en) | 2007-03-02 | 2012-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
US20090076734A1 (en) | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
US20080234946A1 (en) | 2007-03-22 | 2008-09-25 | University Of South Florida | Predictive radiosensitivity network model |
WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
US8112237B2 (en) * | 2009-03-11 | 2012-02-07 | Progress Rail Services Corp. | System and method for correcting signal polarities and detection thresholds in a rail vehicle inspection system |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5651964A (en) * | 1990-12-04 | 1997-07-29 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by the adenoviral EIA gene |
US5516631A (en) | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
DE69426841T2 (de) * | 1993-02-16 | 2001-09-06 | Onyx Pharma Inc | Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie |
US5821733A (en) * | 1994-02-22 | 1998-10-13 | Packard Bell Nec | Multiple cell and serially connected rechargeable batteries and charging system |
US5776743A (en) * | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
-
1994
- 1994-09-06 US US08/301,316 patent/US5776743A/en not_active Expired - Fee Related
-
1995
- 1995-09-05 AT AT95933746T patent/ATE266425T1/de not_active IP Right Cessation
- 1995-09-05 DK DK95933746T patent/DK0781092T3/da active
- 1995-09-05 DE DE69533036T patent/DE69533036T2/de not_active Expired - Fee Related
- 1995-09-05 PT PT95933746T patent/PT781092E/pt unknown
- 1995-09-05 CA CA002199265A patent/CA2199265A1/en not_active Abandoned
- 1995-09-05 JP JP08509670A patent/JP2000510435A/ja not_active Ceased
- 1995-09-05 ES ES95933746T patent/ES2216018T3/es not_active Expired - Lifetime
- 1995-09-05 EP EP95933746A patent/EP0781092B1/en not_active Expired - Lifetime
- 1995-09-05 WO PCT/US1995/011342 patent/WO1996007322A1/en active IP Right Grant
-
1997
- 1997-05-09 US US08/853,831 patent/US6100243A/en not_active Expired - Fee Related
-
2000
- 2000-02-23 US US09/510,885 patent/US6544955B1/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
JP5580043B2 (ja) * | 2007-04-27 | 2014-08-27 | オンコリスバイオファーマ株式会社 | 放射線増感増強剤 |
Also Published As
Publication number | Publication date |
---|---|
DE69533036D1 (de) | 2004-06-17 |
DK0781092T3 (da) | 2004-08-30 |
US6544955B1 (en) | 2003-04-08 |
ES2216018T3 (es) | 2004-10-16 |
DE69533036T2 (de) | 2005-05-19 |
EP0781092A4 (en) | 1998-09-30 |
WO1996007322A1 (en) | 1996-03-14 |
AU3627895A (en) | 1996-03-27 |
US6100243A (en) | 2000-08-08 |
CA2199265A1 (en) | 1996-03-14 |
ATE266425T1 (de) | 2004-05-15 |
US5776743A (en) | 1998-07-07 |
EP0781092A1 (en) | 1997-07-02 |
AU693604B2 (en) | 1998-07-02 |
PT781092E (pt) | 2004-09-30 |
EP0781092B1 (en) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000510435A (ja) | アデノウイルスe1aを用いて腫瘍細胞を感作する方法 | |
JP3847334B2 (ja) | DNA損傷剤およびр53を含有する組成物 | |
JP6956159B2 (ja) | 腫瘍溶解性アデノウイルスによる脳癌の処置方法 | |
Safak et al. | Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells | |
Li et al. | Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo | |
Wang et al. | The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy | |
PL186151B1 (pl) | Zrekombinowane adenowirusy, kompozycje zawierające zrekombinowane adenowirusy, komórka gospodarza zainfekowana zrekombinowanym adenowirusem oraz sposób otrzymywania biologicznie aktywnego białka p53 typu dzikiego | |
JP6250631B2 (ja) | 微小胞及びその製造方法 | |
JP2001508290A (ja) | 新形成の治療及び予防のための細胞変性ウイルス | |
JP2012502621A (ja) | 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルス療法への感受性 | |
JP2002508187A (ja) | P53+新生細胞の選択的殺死及び診断 | |
JPH11510380A (ja) | p16発現構築物および癌治療におけるその適用 | |
US20210038661A1 (en) | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor | |
Adrover et al. | Hippocampal infection with HSV‐1‐derived vectors expressing an NMDAR1 antisense modifies behavior | |
Shirakawa et al. | Drug‐resistant human bladder‐cancer cells are more sensitive to adenovirus‐mediated wild‐type p53 gene therapy compared to drug‐sensitive cells | |
JP2001521387A (ja) | アポトーシス誘発タンパク質vp2および/またはアポプチンを発現する遺伝子伝達体 | |
JP4117367B2 (ja) | 腫瘍にあるサイクリンg1の発現を阻害する薬剤、その発現伝達体、およびベクター | |
JP2001512302A (ja) | ウイルス感染および腫瘍抑制に関与する哺乳動物遺伝子 | |
WO1995005738A1 (en) | Anticancer agents and apoptosis | |
Wang et al. | Duchenne muscular dystrophy treatment with lentiviral vector containing mini‐dystrophin gene in vivo | |
AU693604C (en) | Method of sensitizing tumor cells with adenovirus E1A | |
EP2734219B1 (en) | Adenovirus e1a fragments for use in anti-cancer therapies | |
JP2003500336A (ja) | (自己)免疫疾患の治療におけるアポトーシス誘発剤の使用 | |
Kaloss et al. | Distribution of retroviral vectors and vector producer cells using two routes of administration in rats | |
KR100217463B1 (ko) | 암억제단백질인 p53을 생산하는 아데노바이러스 및 이를 항암치료에 사용하는 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050608 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050725 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20051024 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051129 |